Acute Myeloid Leukemia

Acute myeloid leukemia drug available in Japan after Nippon Shinyaku launch

Published in Blood Weekly, January 6th, 2005

Cell Therapeutics, Inc. (CTIC) announced that Nippon Shinyaku Co., Ltd. has launched Trisenox (arsenic trioxide) in Japan after receiving pricing approval from the Japanese Ministry of Health to market the drug for patients with relapsed or refractory acute promyelocytic leukemia (APL).

CTI markets Trisenox in the United States and Europe.

CTI also announced that it has signed agreements with 5 new distributors of Trisenox in Latin America, Eastern Europe, Israel, Turkey and South Africa. Earlier this year, the company announced that the U.S. Patent and Trademark office had issued a patent directed to Trisenox, extending CTI's marketing exclusivity...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-01-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database